Is Abiraterone Effective When Administered Without Chemotherapy in Hormone-Resistant Prostate Cancer?

According to a study published recently in the British Medical Journal, abiraterone treatment is effective even when chemotherapy is not administered in advanced-stage, hormone-resistant (resistant to androgen-deprivation therapy) prostate cancer, and long-term use of this drug does not increase side effects.
Previously, when prostate cancer spread, patients entered a period in which there was little that could be done. Later, it was determined that androgens (male hormones) play a role in the development of prostate cancer, and androgen-deprivation therapy became a standard treatment approach for metastatic (advanced-stage) prostate cancer. The initial response to this treatment was quite good. However, after a while, it was observed that resistance to androgen deprivation developed in the body as a result of genetic abnormalities in the sites where androgens bind in the body. From that point onward, the primary aim of the strategies adopted was to prolong life as much as possible.
At present, the chemotherapy drug docetaxel, which provides some benefit in terms of survival, is accepted as the standard treatment for prostate cancer that has become resistant to androgen deprivation. However, no standard treatment approach has yet been developed when the disease does not respond to docetaxel-based treatments or when this response is no longer obtained after a period of time. At this point, several treatment options are available to prolong life. The most important of these is abiraterone acetate. Abiraterone is a drug that works by inhibiting an enzyme involved in androgen synthesis and reducing the amount of androgens. It is already known that abiraterone prolongs survival after chemotherapy in prostate cancer that has become resistant to androgen deprivation. However, this study was conducted to observe whether abiraterone would be effective when used without chemotherapy, that is, without administering docetaxel treatment.
In the study, 1088 men with hormone-resistant prostate cancer who had not yet received chemotherapy were divided into 2 groups: those who received abiraterone and those who did not, and the patients were followed for approximately 2 years. When the results were examined, fewer deaths were observed among those who received abiraterone, and their survival times were slightly longer. In addition, it was observed that among those who received abiraterone, the need to start chemotherapy and opiate use (narcotic painkillers for cancer-related pain) arose later, and PSA levels indicating that the cancer was progressing began to rise later.
In conclusion, while hormone-resistant prostate cancer had been synonymous with death for many years, multiple treatment approaches are now available to prolong life in these patients. The current focus is on identifying the ideal approach in procedures such as the timing, sequencing, and dosage of these treatments. In this regard, the fact that abiraterone can be effective without chemotherapy, as well as the fact that long-term use of the drug does not increase its side effects, is an extremely important and encouraging development. My greatest wish is that we will continue to receive and share such encouraging news with you.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.